ESR1 and breast carcinoma: Approximately 70% of newly diagnosed breast cancer express the estrogen receptor (ER) α or β; its presence has primed the development of a number of drugs aimed at interfering with estrogen synthesis, their binding to the receptor, or intracellular ER signaling, in a therapeutic approach designated “endocrine therapy”.